Literature DB >> 26654613

The treatment of nursing home-acquired pneumonia using a medically intensive Hospital in the Home service.

Michael Montalto1, Man Yee Chu2, Irani Ratnam3, Tim Spelman3, Karin Thursky4.   

Abstract

OBJECTIVES: To compare the outcomes for patients with nursing home-acquired pneumonia (NHAP) treated completely in a Hospital in the Home (HITH) setting with those of patients treated in a traditional hospital ward.
DESIGN: Case-control study. SETTING AND PARTICIPANTS: All patients admitted by the Royal Melbourne Hospital for treatment of NHAP from 1 July 2013 to 31 January 2014. INTERVENTION: Admission to the Royal Melbourne Hospital HITH Unit within 48 hours of presentation. MAIN OUTCOME MEASURES: Length of stay, in-hospital and 30-day mortality, hospital readmissions (30-day), complications and unplanned returns to hospital.
RESULTS: Sixty HITH patients and 54 hospital (control) patients were identified. Thirty-two patients (53%) were admitted directly to HITH without any hospital or emergency stay, 25 (42%) were referred directly from the emergency department. HITH patients were more likely to be male, older and dehydrated, and less likely to have an advanced care directive or to have had non-invasive ventilation. There were no significant differences in CURB-65 or CORB scores between the two patient groups; similar proportions were given intravenous fluids or supplemental oxygen. There were no adjusted differences in median length of stay between HITH and control patients (-1.00 days; 95% CI, -2.72 to 0.72; P = 0.252) or in overall mortality at 30 days (HITH v control patients: adjusted odds ratio [aOR], 1.97; 95% CI, 0.67-5.73). Inpatient mortality was lower for HITH patients (aOR, 0.19; 95% CI, 0.05-0.75) but unadjusted postdischarge 30-day mortality was higher (OR, 13.25; 95% CI 1.67-105.75). There were no differences between the two groups with regard to complications (falls and pressure wounds) and 30-day readmission rates (aOR, 1.59; 95% CI, 0.30-8.53).
CONCLUSIONS: This study suggests that HITH may be an effective and safe alternative to hospital treatment for residents of aged care facilities presenting with NHAP.

Entities:  

Mesh:

Year:  2015        PMID: 26654613     DOI: 10.5694/mja15.00672

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Nursing home patients and Emergency Department attendance in a single urban Irish catchment area: an observational study surrounding the introduction of a community medicine for older person service.

Authors:  Christine E Mc Carthy; Tracy Keating; Vinny Ramiah; Dermot Power; Joseph Duggan; Chie Wei Fan
Journal:  Ir J Med Sci       Date:  2020-05-29       Impact factor: 1.568

Review 2.  Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist.

Authors:  Toni Docherty; Jennifer J Schneider; Joyce Cooper
Journal:  Pharmacy (Basel)       Date:  2020-12-07

3.  Site of care and factors associated with mortality in unvaccinated Australian aged care residents during COVID-19 outbreaks.

Authors:  Nicholas J Radcliffe; Liza Lau; Emma Hack; Andrew Huynh; Arvind Puri; Henry Yao; Aaron Wong; Sabrina Kohler; Maggie Chua; Sanka Amadoru; Cilla Haywood; Paul Yates
Journal:  Intern Med J       Date:  2022-08-25       Impact factor: 2.611

4.  Root Cause Analysis to Identify Medication and Non-Medication Strategies to Prevent Infection-Related Hospitalizations from Australian Residential Aged Care Services.

Authors:  Janet K Sluggett; Samanta Lalic; Sarah M Hosking; Brett Ritchie; Jennifer McLoughlin; Terry Shortt; Leonie Robson; Tina Cooper; Kelly A Cairns; Jenni Ilomäki; Renuka Visvanathan; J Simon Bell
Journal:  Int J Environ Res Public Health       Date:  2020-05-08       Impact factor: 3.390

5.  Integration of Inpatient and Residential Care In-Reach Service Model and Hospital Resource Utilization: A Retrospective Audit.

Authors:  Jie-Min Kwa; Meg Storer; Ronald Ma; Paul Yates
Journal:  J Am Med Dir Assoc       Date:  2020-09-11       Impact factor: 4.669

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.